Human immune response to epitopes on the meningococcal outer membrane class 5 protein following natural infection

FEMS Immunology and Medical Microbiology

Volumn 15, Issue 2-3, 1996, Pages 159-168

  Danelli, M G M ^a,b,c   Alves, C M A ^a   Bastos, R C ^a   Batoreu, N M ^a   Barroso, D E ^a   Peralta, J M ^b   Frasch, C E ^d  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL RURAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Class 5 protein; Monoclonal antibody; Neisseria meningitidis

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; OUTER MEMBRANE PROTEIN; VACCINE;

ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOBLOTTING; MENINGITIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL;

EID: 0030248303     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/0928-8244(96)00058-2     Document Type: Article

References (32)

1. [1] Tettmer, R.E., Abbott J.D. and Jones, D.M. (1977) Meningococcal meningitidis in Royal Air Force recruits. Pub. Heath. 91, 253-255.
2. [2] Banerjee-Bhatnagar, N. and Frasch, C.E. (1990) Expression of Neisseria meningitidis iron-regulated outer membrane proteins, including a 70-kilodakon transferrin receptor and their potential for use as vaccines. Infect. Immun. 58, 2875-2881.
3. [3] Lifely, M.R., Moreno, C. and Lindon, J.C. (.1987) An integrated molecular and immunological approach towards a meningococcal group B vaccine. Vaccine 5, 11-26.
4. [4] Frasch, C.E., Zahradnik, J.M., Wang, L.Y., Mocca, L.F. and Tsai, C.M. (1988) Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotype 2b protein-group B polysaccharide vaccine. J. Infect. Dis. 158, 710-718.
5. [5] Zollinger, W.R., Mandrell, R.E., Griffiss, J.M., Altieli, P. and Berman, S. (1979) Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J. Clin. Invest. 63, 836-848.
6. [6] Sierra, G.V.G., Campa, H.C., Varcacel N.M., Garcia, I.L., Izquierdo, P.L., Sotolongo, P.F., Valcarcel, N.M., Casnueva, G.V., Baro, M.S., Leguen, C.F., Rodrigues, C.R. and Terry, M.H. (1991) Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14, 195-207.
7. [7] De Morais, J.C., Perkins, B.A., Camargo, M., Hidalgo, N.T.R. Barbosa, H.A. Sacchi C.T., Gral, I.M.L., Gatas, V.L., Vasconcelos, H.G., Plikaytis, B.D., Wenger, J.D. and Broome, C.V. (1992) Protective efficacy of a serogroup B meningococcal vaccine in São Paulo, Brazil Lancet 340, 1077-1078.
8. [8] Bjune, G., Hoiby, E.A., Gronnesby, J.K., Arnesen O., Fredriksen, J.H. Halstensen, A. Holten, E., Lindbak, A.K., Nokleby, H., Rosenqvist, E., Solberg, L.K., Closs, O., Eng, J., Froholm, L.O., Lystad, A., Baketeig, L.S. and Hareide, B. (1991) Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338, 1093-1096.
9. [9] Zollinger, W.L., Boslego, J., Moran, E., Garcia, J., Cruz. C. and Ruiz, S. (1991) Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. NIPH. Ann. 14, 211-213.
10. [10] DeVoe, I.W. and Gilchrist, J.E. (1973) Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis. J. Exp. Med. 138, 1156-1167.
11. [11] Sacchi, C.T., Pessoa, L.L., Ramos, S.R., Milagres, L.G., Camargo, M.C.C., Hidalgo, N.T.R., Melles, C.E.A., Caugant, D.A. and Frasch, C.E. (1992) Ongoing group B Neisseria meningitidis epidemic in São Paulo, Brazil due to increased prevalence of a single clone of the ET-5 complex. J. Clin. Microbiol. 30, 1734-1738.
12. [12] Black, J.R. Black, W.J. and Cannon, J.G. (1986) Neisserial antigen H.8 is immunogenic in patients with disseminated gonococcal and meningococcal infections. J. Infect. Dis. 151, 650-657.
13. [13] Mandrell, R.E. and Zollinger, W.D. (1989) Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination. Infect. Immun. 57, 1590-1598.
14. [14] Estabrook, M.M., Mandrell, R.E., Apicella, M.A. and Griff-iss, J.M. (1990) Measurement of the human immune response to meningococcal lipooligosaccharide antigens by using serum to inhibit monoclonal antibody binding to purified lipooligosaccharide. Infect. Immun. 58, 2204-2213.
15. [15] Danelli, M.G.M., Batoreu, N.M., Lacerda, M.D., Ferreira, C.R.B., Cardoso, J.D., Peralta, J.M. and Frasch, C.E. (1995) Surface antigens analysis of group B Neisseria meningitidis outer membrane by monoclonal antibodies. Identification of bactericidal antibodies to class 5 protein. Curr. Microbiol. 31, 146-151.
16. [16] Poolman, J.T., Marie, S. and Zanen, H.C. (1980) Variability of low-molecular-weight, heat-modifiable outer membrane proteins of Neisseria meningitidis. Infect. Immun. 30, 642-648.
17. [17] Poolman, J.T., Hopman, C.T.T. and Zanen, H.C. (1983) Immunogenicity of meningococcal antigens as detected in patients sera. Infect. Immun. 40, 398-406.
18. [18] Poolman, J.T., Hopman, C.T.P. and Zanen, H.C. (1980) Immunochemical characterization of Neisseria meningitidis serotype antigens by immunodiffusion and SDS-polyacrylamide gel electrophoresis immunoperoxidase techniques and the distribution of the serotypes among cases and carries. J. Gen. Microbiol. 116, 465-473.
19. [19] Catlin, W.B. (1973) Nutritional profiles of Neisseria gonorrhoeae. Neisseria meningitidis and Neisseria lactamica in defined media and the use of growth requirements for gonococcal typing. J. Infect. Dis. 128, 178-194.
20. [20] Archibald, S.F. and DeVoe, L.W. (1980) Iron Acquisition by Neisseria meningitidis in vitro. Infect. Immun. 27, 322-334.
21. [21] Lowry, O.H., Rosebrough, J.N., Farr, A.L. and Randall, R.L. (1951) Protein measurement with the folin phenol reagent. J. Biol. Chem. 193, 265-275.
22. [22] Arakere, G. and Frasch, C.E. (1991) Specificity of antibodies to O-acetyl positive and O-acetyl negative group C meningococcal polysaccharides in sera from vaccinees and carriers. Infect. Immun. 59, 4349-4353.
23. [23] Nakane, P.K. and Kawaoi, A. (1974) Peroxidase-labeled antibody. A new method of conjugation. J. Histochem. Citochem. 22, 1084-1091.
24. [24] Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
25. [25] Tsang, V.C.W., Peralta, J.M. and Simons, R.A. (1983) Enzyme-linked immunoelectrotransfer blot techniques (EITB) for studying the specificities of antigens and antibodies separated by gel electrophoresis. Methods Enzymol. 92, 377-391.
26. [26] Zollinger, W.D. and Moran, E. (1991) Meningococcal vaccine-present and future. Trans. Roy. Soc. Trop. Med. Hyg. 85 (Suppl. 1), 37-43.
27. [27] Zollinger, W.D., Moran, E., Connelly, H., Mandrell, R. and Brandt, B. (1984) Monoclonal antibodies to serotype 2 and subtype 15 outer membrane protein and their use in serotyping. Infect. Immun. 46, 260-266.
28. [28] Frasch, C.E. and Mocca, L.F. (1978) Heat-modifiable outer membrane proteins in Neisseria meningitidis and their organization within the membrane. J. Bacteriol. 136, 1127-1134.
29. [29] Swanson, J. (1981) Surface-exposed protein antigens of the gonococcal outer membrane. Infect. Immun. 34, 804-816.
30. [30] Wedege, E. and Frohom. L.O. (1986) Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunobloting. Infect. Immun. 51, 571-578.
31. [31] Achtman, M., Neibert, M., Crowe, B.A., Strittmatter, W., Kusecek, B., Weyse, E., Walsh, M.J., Slawig, B., Morelli, G., Moll, A. and Blake, M. (1988) Purification and characterization of eight class 5 outer membrane protein variants from a clone of Neisseria meningitidis serogroup A. J. Exp. Med. 168, 507-525.
32. [32] Reed, L.J. and Muench, H. (1938) A simple method of estimating fifty percent endpoint. Am. J. Hyg. 27, 493-497.